N-{5-[(R)-2-benzylamino-1-(tert-butyldimethylsilanyloxy)ethyl]-2-benzyloxyphenyl}formamide | 953393-96-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-{5-[(R)-2-benzylamino-1-(tert-butyldimethylsilanyloxy)ethyl]-2-benzyloxyphenyl}formamide
• 英文别名: N-[5-[(1R)-2-(benzylamino)-1-[tert-butyl(dimethyl)silyl]oxyethyl]-2-phenylmethoxyphenyl]formamide
• CAS: 953393-96-9
• 化学式: C₂₉H₃₈N₂O₃Si
• 分子量: 490.718
• InChiKey: PALVEVDAIMYSPY-NDEPHWFRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.69
• 重原子数：
  35
• 可旋转键数：
  12
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.34
• 拓扑面积：
  59.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-{5-[(R)-2-benzylamino-1-(tert-butyldimethylsilanyloxy)ethyl]-2-benzyloxyphenyl}formamide 、 溶剂黄146 在 氮气 、 氢氧化钯 、 氢气 、 乙酸乙酯 作用下， 以 甲醇 为溶剂， 反应 12.0h， 以to provide N-{5-[(R)-2-amino-1-(tert-butyldimethylsilanyloxy)ethyl]-2-hydroxyphenyl}formamide acetic acid salt (48 g, 98% purity) as a yellow-white solid的产率得到N-{5-[(R)-2-amino-1-(tert-butyldimethylsilanyloxy)ethyl]-2-hydroxyphenyl}-formamide acetic acid salt
  参考文献：
  名称：

  Crystalline forms of a dimethylphenyl compound

  摘要：

  本发明涉及二苯基-2-基甲酸1-[2-(4-{[(R)-2-(3-甲酰胺基-4-羟基苯基)-2-羟乙基氨基]甲基}-2,5-二甲基苯基氨基甲酰)乙基]哌啶-4-基酯的晶体游离碱形式或其溶剂结晶体。本发明还涉及含有或由这种晶体形式制备的制药组合物；用于制备这种晶体形式的有用中间体和过程；以及使用这种晶体形式治疗肺部疾病的方法。

  公开号：

  US20070249674A1
• 作为产物：
  描述：

  (R)-2-bromo-1-tert-butyldimethylsilyloxy-1-(3-formamido-4-benzyloxyphenyl)ethane 、 苄胺 在 氮气 、 水 、 乙酸乙酯 、 Brine 、 magnesium sulfate 作用下， 以 N-甲基吡咯烷酮 为溶剂， 反应 8.0h， 以to provide crude N-{5-[(R)-2-benzylamino-1-(tert-butyldimethylsilanyloxy)ethyl]-2-benzyloxyphenyl}formamide (100 g, 90% yield, 75-80% purity) as an orange-brown thick oil的产率得到N-{5-[(R)-2-benzylamino-1-(tert-butyldimethylsilanyloxy)ethyl]-2-benzyloxyphenyl}formamide
  参考文献：
  名称：

  Crystalline forms of a dimethylphenyl compound

  摘要：

  本发明涉及二苯基-2-基甲酸1-[2-(4-{[(R)-2-(3-甲酰胺基-4-羟基苯基)-2-羟乙基氨基]甲基}-2,5-二甲基苯基氨基甲酰)乙基]哌啶-4-基酯的晶体游离碱形式或其溶剂结晶体。本发明还涉及含有或由这种晶体形式制备的制药组合物；用于制备这种晶体形式的有用中间体和过程；以及使用这种晶体形式治疗肺部疾病的方法。

  公开号：

  US20070249674A1

文献信息

• Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
  申请人：Colson Pierre-Jean

  公开号：US20070249675A1

  公开（公告）日：2007-10-25

  This invention relates to compounds of formula I: wherein R 1 and R 2 are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The invention also relates to pharmaceutical compositions and combinations comprising such compounds, processes and intermediates for preparing such compounds, and methods of using such compound to, for example, treat pulmonary disorders, such as chronic obstructive pulmonary disease and asthma.

  本发明涉及式I的化合物：其中R1和R2如规范中定义，或其药用可接受的盐或溶剂或立体异构体。该发明还涉及包含这类化合物的药物组合物和配方，用于制备这类化合物的过程和中间体，以及使用这类化合物治疗肺部疾病，如慢性阻塞性肺病和哮喘等方法。
• Crystalline forms of a dimethylphenyl compound
  申请人：Bolton Jennifer

  公开号：US20070249674A1

  公开（公告）日：2007-10-25

  The invention relates to crystalline free base forms of biphenyl-2-ylcarbamic acid 1-[2-(4-[(R)-2-(3-formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]methyl}-2,5-dimethylphenylcarbamoyl)ethyl]piperidin-4-yl ester or a solvate thereof. This invention also relates to pharmaceutical compositions containing or prepared from such crystalline forms; processes and intermediates useful for preparing such crystalline forms; and methods of using such crystalline forms to, for example, treat a pulmonary disorder.

  该发明涉及联苯基-2-基氨基甲酸1-[2-(4-[(R)-2-(3-甲酰氨基-4-羟基苯基)-2-羟乙基氨基]甲基}-2,5-二甲基苯基甲酰)乙基]哌啶-4-基酯的结晶游离碱形式或其溶剂合物。该发明还涉及含有或由这种结晶形式制备的药物组合物；用于制备这种结晶形式的有用中间体和过程；以及使用这种结晶形式来治疗肺部疾病等方法。
• CRYSTALLINE FORMS OF A DIMETHYLPHENYL COMPOUND
  申请人：BOLTON Jennifer

  公开号：US20110086881A1

  公开（公告）日：2011-04-14

  The invention relates to crystalline free base forms of biphenyl-2-ylcarbamic acid 1-[2-(4-[(R)-2-(3-formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]methyl}-2,5-dimethylphenylcarbamoyl)ethyl]piperidin-4-yl ester or a solvate thereof. This invention also relates to pharmaceutical compositions containing or prepared from such crystalline forms; processes and intermediates useful for preparing such crystalline forms; and methods of using such crystalline forms to, for example, treat a pulmonary disorder.

  本发明涉及二苯基-2-基氨基甲酸1-[2-(4-[(R)-2-(3-甲酰氨基-4-羟基苯基)-2-羟基乙基氨基]甲基}-2,5-二甲基苯基甲酰)乙基]哌啶-4-酯或其溶剂的结晶无水基形式。本发明还涉及含有或由这种结晶形式制备的制药组合物；用于制备这种结晶形式的有用中间体和工艺；以及使用这种结晶形式治疗肺部疾病等方法。
• DIALKYLPHENYL COMPOUNDS HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
  申请人：Colson Pierre-Jean

  公开号：US20100137603A1

  公开（公告）日：2010-06-03

  This invention relates to compounds of formula I: wherein R 1 and R 2 are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The invention also relates to pharmaceutical compositions and combinations comprising such compounds, processes and intermediates for preparing such compounds, and methods of using such compound to, for example, treat pulmonary disorders, such as chronic obstructive pulmonary disease and asthma.

  本发明涉及I式化合物： 其中R1和R2如本说明书所定义，或其药学上可接受的盐、溶剂或立体异构体。本发明还涉及包括这种化合物的药物组合物和制备这种化合物的中间体和过程，以及使用这种化合物的方法，例如用于治疗肺部疾病，如慢性阻塞性肺疾病和哮喘。
• Dialkylphenyl compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
  申请人：Theravance, Inc.

  公开号：US07524965B2

  公开（公告）日：2009-04-28

  This invention relates to compounds of formula I: wherein R1 and R2 are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The invention also relates to pharmaceutical compositions and combinations comprising such compounds, processes and intermediates for preparing such compounds, and methods of using such compound to, for example, treat pulmonary disorders, such as chronic obstructive pulmonary disease and asthma.

  本发明涉及式I的化合物：其中R1和R2如规范中定义，或其药用盐、溶剂或立体异构体。本发明还涉及包含这种化合物的药物组合物和制剂，制备这种化合物的过程和中间体，以及使用这种化合物的方法，例如用于治疗肺部疾病，如慢性阻塞性肺疾病和哮喘。